Citations

Clear

16280 citation(s) found for "Yu, David".

Utility of Endoscopic Endonasal Cyst Fenestration and Marsupialization in the Treatment of Pediatric Craniopharyngioma
Rich, David, Venkatesh, Sanjena , Kohanski, Michael A. , Adappa, Nithin D. , Storm, Phillip B. , Lerner, David K. , Rich, Dominick, Workman, Alan D. , Barnett, Sarah, Eide, Jacob G. , Kundishora, Adam J. , Douglas, Jennifer E , Adappa, Nithin D.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803396 Get It

Clinical and Imaging Findings Suggest Clonal Resistance to Dopamine Agonist Therapy in a Subset of Medically Refractory Prolactinomas
Peters, David G. , Shinya, Yuki , Gompel, Jamie J. Van , Peters, David

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803183 Get It

Assessing Radiographic Predictors of Orbital Recurrence in Olfactory Neuroblastoma: A Novel Grading System for Orbital Involvement
Graves, Jeffrey , Iyoha, Ehiremen, Haller, Travis J. , Celda, María Peris, Link, Michael J. , Moore, Eric J. , Stokken, Janalee K., Bauman, Megan M. J. , Olson, Brennan , Pinheiro‐Neto, Carlos , Routman, David M. , Shlapak, Darya P. , DeLone, David R. , Wagner, Lilly H. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803171 Get It

The Impact of Program and Geographic Signaling on Anesthesia Residency Applications, Interviews, and the Match
Dutoit, Andrea P. , Teeter, Emily G. , Wolpaw, Jed , Martin, Timothy W. , Manohar, Crystal , Long, Timothy R. , Abramowicz, Apolonia E. , Stahl, David L. , Shostrom, Valerie , Hoffman, Julie, Martinelli, Susan M. , Hoffman, Julie T.

Mayo Clinic

Anesthesia & Analgesia | February 7, 2025 | Volume: 141 | Issue: 4 | Pages: 876-883

10.1213/ane.0000000000007443 | PMID 39919023 Get It

BACKGROUND: Increased specialty competitiveness, alongside the inception of virtual interviews, has increased the number of applications submitted to the Electronic Residency Application Service (ERAS) in anesthesiology. ERAS introduced signals to provide applicants with a means to demonstrate interest in a select group of residency programs. In the 2023 to 2024 application cycle, anesthesiology applicants had the opportunity to send 5 gold and 10 silver signals in a tiered system. METHODS: This multicenter, cross-sectional (exempt) research survey was created by members of the executive council of the Association of Anesthesiology Core Program Directors (AACPD) and housed and distributed through REDCap and the University of Nebraska Medical Center. Publicly available contact information of anesthesiology core program directors was obtained from the Accreditation Council for Graduate Medical Education (ACGME) website and membership roster of the AACPD. In total, 174 anesthesiology programs were identified. A survey invitation was distributed on March 12, 2024, to all programs via e-mail with reminders. The survey closed on April 30, 2024. Survey responses were collected anonymously, with instructions to provide 1 response per program. All statistical summaries and analyses were performed using SAS 9.3 (SAS Institute). RESULTS: The survey was sent to all 174 identified programs, with a response rate of 48.9%. Small programs were defined as having <44 residents, medium 44 to 62 residents, and large >62 residents. Small programs received significantly fewer applications (median 1255) than medium (1420) and large (1558) programs ( P = .0005). There was a statistically significant difference in the number of gold signals received based on program size, with large programs receiving significantly more than medium (169 vs 116, P = .0238) or small programs (168 vs 71, P < .0001). Applicants sending gold signals were more likely to receive an interview compared to those who sent silver signals (56.7% vs 31%, P ≤ .0001). Of the those interviewed, applicants who sent gold signals comprised 42% (28.7%–52.6%), whereas applicants who sent silver signals comprised 45.5% (33%–54.7%). Applicants who did not send a program signal but signaled geographically made up a smaller portion of the interview group at 3% (0%–15.4%). The percentage of matched residents sending gold signals made up 66.7% (47.1%–82.4%) of a program’s match list, whereas those sending silver signals were 25% (11.1%–33.3%) of the matched cohort. CONCLUSIONS: Anesthesiology applicants who sent program signals were selected for a large majority of available interview positions, and interviewed applicants who submitted gold and silver signals comprised the vast majority of matched resident cohorts.
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study
Luskin, Marlise R. , Yin, Jun , Lozanski, Gerard , Curran, Emily , Malnassy, Gregory , Mrózek, Krzysztof , Bloomfield, C. D., Fulton, Noreen, Kolitz, Jonathan E. , LaPlant, Betsy, Kour, Oudom, Powell, Bayard L., Vij, Ravi , Grinblatt, David L. , Stone, Richard M. , Wang, Eunice S. , Larson, Richard A , Luskin, Marlise R , Cataland, Spero R. , Uy, Geoffrey L. , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Cancer | February 7, 2025 | Volume: 131 | Issue: 4 | Pages: No page available

10.1002/cncr.35750 | PMID 39916320 Get It

AbstractBackgroundAcute lymphoblastic leukemia (ALL) in adults is aggressive, with long‐term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B‐ and T‐lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity.MethodsIn this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single‐agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility.ResultsThe study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow‐up of 101.2 months, median overall survival (OS) was 26.3 months (3‐year rate, 44%; 5‐year rate, 36%; 10‐year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease‐free survival between patients who did and who did not receive alemtuzumab.ConclusionAlemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.
Objective Grading of Tonography Tracings for the Measurement of Outflow Facility
Sit, Arthur J. , Gulati, Vikas , Kazemi, Arash , Gilbert, Jesse, Fan, Shan , Hodge, David O. , Sit, Arthur J , Toris, Carol B. , Reed, David M. , Moroi, Sayoko E.

Mayo Clinic

Translational Vision Science & Technology | February 6, 2025 | Volume: 14 | Issue: 2 | Pages: 10

10.1167/tvst.14.2.10 | PMID 39913125 Get It

Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Metagenomic Insights into Microbial Signatures in Thrombi from Acute Ischemic Stroke Patients Undergoing Endovascular Treatment
Thirupathi, K., Ghozy, Sherief , Reda, Abdullah , Ranatunga, Wasantha , Mars, Ruben A. , Armin, Zarrintan, Mereuta, Oana Madalina , Prabhjot, Sekhon, Brinjikji, Waleed , Kallmes, David F, Kadirvel, Ramanathan , Thirupathi, Kasthuri, Ranatunga, Wasantha K, Ruben, Mars A , Madalina Mereuta, Oana , Ghozy, Sherief , Reda, Abdullah , Thirupathi, Kasthuri, Dai, Daying , Kallmes, David F.

Mayo Clinic

Brain Sciences | February 6, 2025 | Volume: 15 | Issue: 2 | Pages: 157

10.3390/brainsci15020157 | PMID 40002490 Get It

Background: Variability in recanalization success during endovascular treatment for acute ischemic stroke (AIS) has led to increased interests in thrombus composition and associated cellular materials. While evidence suggests that bacteria may influence thrombus characteristics, limited data exist on microbiological profiles of thrombi in stroke patients. Objectives: Characterization of bacterial communities present in thrombi of AIS patients undergoing mechanical thrombectomy, providing insights into microbial contributions to stroke pathogenesis and treatment outcomes. Methods: Thrombi were collected from 20 AIS patients. After extracting metagenome, 16S rDNA sequencing was performed. Bioinformatic analysis included taxonomy and diversity assessments. The presence of bacterial DNA and viable bacteria in thrombi was validated using polymerase chain reaction (PCR) and bacterial culturing followed by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) analysis, respectively. Results: 16S rDNA was amplified in 19/20 thrombi (95%). Analysis identified a diverse microbial community, with Corynebacterium spp. as the most prevalent genus, followed by Staphylococcus spp., Bifidobacterium spp., Methylobacterium spp., and Anaerococcus spp. Alpha diversity analyses (Shannon index: 4.0–6.0 and Simpson index: 0.8–1.0) revealed moderate to high microbial diversity across samples; beta diversity demonstrated distinct clustering, indicating inter-patient variability in microbial profiles. PCR confirmed the presence of DNA specific to dominant bacterial taxa identified through sequencing. Culturing showed the presence of Staphylococcus epidermidis and Enterococcus faecalis in some clots as identified through MALDI analysis. Conclusions: This study shows bacterial communities present in AIS patients’ thrombi, suggesting a potential link between microbial signatures and thrombus characteristics.